Cassava Sciences (SAVA) falls to a new 52-week low. A CUNY report shows “egregious misconduct” in SAVA’s research. The report highlights that they found questionable data management and record keeping. Twenty of the research papers in question provided “key support” for Simufilam, the company’s Alzheimer’s drug. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.
Market On Close
13 Oct 2023
SHARE
Morning Trade Live
27 Mar 2024
Next Gen Investing
23 Mar 2024
Morning Trade Live
15 Apr 2024
Morning Trade Live
12 Mar 2024
Morning Trade Live
26 Mar 2024
Next Gen Investing
21 Feb 2024